Verici Dx PLC
Company Profile
- Business description- Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients. 
- Contact- 19 Stanwell Road 
 Avon House
 Penarth
 CardiffCF64 2EZ
 GBR- T: +44 2920710570 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Diagnostics & Research - Fiscal Year End- 31 December 2025 - Employees- 15 
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,221.10 | 14.40 | 0.16% | 
| CAC 40 | 8,157.29 | 43.59 | -0.53% | 
| DAX 40 | 24,118.89 | 5.32 | -0.02% | 
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% | 
| FTSE 100 | 9,760.06 | 3.92 | 0.04% | 
| HKSE | 26,245.19 | 37.50 | -0.14% | 
| NASDAQ | 23,581.14 | 377.33 | -1.57% | 
| Nikkei 225 | 51,946.83 | 621.22 | 1.21% | 
| NZX 50 Index | 13,549.05 | 89.76 | 0.67% | 
| S&P 500 | 6,822.34 | 68.25 | -0.99% | 
| S&P/ASX 200 | 8,923.60 | 10.40 | 0.12% | 
| SSE Composite Index | 3,972.71 | 14.19 | -0.36% |